The insulin-like growth factor binding protein (IGFBP) family is a critical component of the insulin-like growth factor (IGF) system which regulate the biological actions of the IGFs and may also be capable of IGFindependent actions. To date, seven distinct IGFBPs have been described. Among these IGFBPs, IGFBPs-1-6 bind IGFs with high affinity, while only IGFBP-7 binds with low affinity. Recently, we have demonstrated that connective tissue growth factor (CTGF) also binds IGFs with low affinity, suggesting that a family of low-affinity IGFBPs, distinct from the highaffinity members, may exist, and together these constitute an IGFBP superfamily. IGFBPs have various biological roles. IGFBPs act not only as a carrier proteins, but also as a modulators of IGF actions by involving in IGF ligand-receptor interactions through influences on both the bioavailability and distribution of IGFs in the extracellular environment. In addition, some IGFBPs (IGFBPs-1, -3, and -5) appears to have intrinsic activity independent of IGFs. This review will focus on recent studies on the biological roles of IGFBPs in IGF-dependent and IGF-independent modes.
Introduction
Insulin-like growth factors (IGFs) are important mitogenic and anabolic polypeptides thought to be involved in normal and malignant cellular proliferation (Daughaday and Rotwein, 1989; Rotwein 1991) . IGFs are structurally related to insulin and have both rapid insulin-like effects and slower growth-promoting, anabolic effects. The biological functions of the IGFs are mediated by a family of transmembrane receptors, which includes the insulin, type 1 and type 2 IGF receptors, but primarily through the type 1 IGF receptor (Massague and Czech, 1982) . The IGFs and insulin comprise a superfamily of ancient, anabolic peptides, represented across the animal phyla (Murray-Rust et al., 1992) . Over the course of evolution, ancestral "insulin-like" gene gave rise to insulin and I G F s , having distinct anabolic roles (Nagamatsu et al., 1991) . These facts are supported by the findings that 1) human IGF-I and proinsulin share an overall amino acid sequence homology of 48% (Rinderknecht and Humbel, 1978) ; and 2) a gene encoding a polypeptide with a deduced sequence that contains features of both insulin and IGFs was detected in the primitive cephalochordate Branchiostoma californiensis (Chan et al., 1990) . However, IGFs differ from insulin in at least two respects: 1) the insulin gene is expressed exclusively in the pancreatic β-cells (Falkmer, 1985) , while the IGFs are expressed in virtually all cell types; and 2) IGFs are bound in biological fluids to the IGF binding proteins (IGFBPs), while insulin reportedly has no affinity for any of the IGFBPs (Rechler, 1993; Rosenfeld et al., 1994) .
At the present time, seven distinct IGFBPs have been described (Lee et al ., 1988; Binkert et al., 1989; Wood et al., 1989; LaTour et al., 1990; Kiefer et al., 1991a, b; Oh et al., 1996) . They share an overall protein sequence homology of 50% and contain 12-18 conserved cysteines in the NH 2 and COOH-terminal regions Oh et al., 1996) . Among of them, IGFBPs -1-6 bind IGFs with high affinity, while IGFBP-7 has relatively low affinity. In addition, we have recently demonstrated that the protein product of the human connective tissue growth factor (CTGF) cDNA is structurally related to the IGFBPs, and specifically binds IGFs, although with relatively low affinity, thereby constituting another new member of the IGFBP family, IGFBP-8 . Based upon our observations, we have proposed that IGFBP-7 and CTGF/IGFBP-8 are members of a family of low-affinity IGFBPs, distinct from the high-affinity members, and together these constitute an IGFBP superfamily. Some structural and genetic characteristics of the high-affinity and low-affinity EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 29, No 2, 85-96, June 1997 IGFBPs are shown in Table 1 .
The IGFBPs have been proposed to have important functions that are essential to regulate the biological activities of the IGFs and may also be capable of IGFindependent actions. These actions are 1) to act as carrier proteins; 2) to prolong the half-lives of the IGFs and regulate their metabolic clearance; 3) to provide a means of functional and /or tissue specificity: such specificity is attained not only through different IGFBPs taking on specialized roles, but, importantly, also through differential post-translational modifications that can alter their biological activity; 4) to directly modulate interaction of the IGFs with their receptors and thereby indirectly regulate the biological actions of the IGFs; and 5) to directly modulate normal and malignant cell growth in some IGFBPs, independent of IGFs (Andress and Birnbaum, 1992; Jones et al., 1993a; Oh et al ., 1993a; Jones and Clemmons, 1995) .
In serum, most of the IGFs (> 90% in adult serum) circulate as a 150-kDa ternary complex (IGF-I or IGF-II, IGFBP-3 and a bound acid-labile subunit) (Martin and Baxter, 1986) . All three subunits are positively regulated by growth hormone (GH) in vivo, and their levels in the circulation are directly correlated with body growth . This high molecular weight ternary complex appears to prevent IGFs and I G F B P -3 from crossing the capillary barrier (Baxter, 1994) , as well as increase the half-life of IGF-I in the circulation to 12-15 hours (Guler et al., 1989) . Meanwhile, the other IGFBPs (IGFBPs-1,-2 and -4) appear to have the ability to cross the capillary barrier, and play an important aspect in the dynamics of the IGF/IGFBP system at the cellular level. The amount of IGFBP-5, -6 and -7 in human serum is relatively low and is unlikely to be of great physiological significance at that level. The relative concentrations of each of the IGFBPs vary among biological fluids; IGFBP-1 is the major IGFBP in human amniotic fluid (Drop et al. , 1979) , and IGFBP-2 is prominent in cerebrospinal fluid and seminal plasma , while IGFBP-3 is the major IGFBP in normal human serum (Martin and Baxter, 1986) . In this paper, we will review recent studies on the biological roles of IGFBPs in controlling cellular actions in cultured cell systems and in whole organisms in IGF-dependent and IGF-independent modes.
IGF-dependent actions of the IGFBPs
Under most conditions, both in vivo and in vitro, the IGFBPs appear to inhibit IGF action, presumably by competing with the IGF receptor for IGF peptides (Zapf et al., 1979) . However, under specific conditions, several of the IGFBPs are also apparently capable of potentiating IGF action, perhaps by facilitating IGF delivery to target receptors (Elgin et al., 1987) . A source of such discrepancy may come from the effects of the several factors that can influence IGF actions. These are 1) the several specific proteases for IGFBPs, which may cleave the binding proteins into fragments that have either significantly reduced or no affinity for IGFs; 2) posttranslational modifications (e.g. phosphorylation); 3) differential localization of the IGFBPs (e.g. on the cell surface or in the extracellular matrix [ECM]); and 4) the direct cellular effects that are not dependent on the IGFs.
Since the extent of posttranslational modifications can alter IGFBP affinity, such as proteolysis, phosphorylation, and glycosylation, effects of IGFBPs on IGF ligandreceptor interactions should be interpreted with caution. Proteolysis occurs with IGFBPs-2-5. After proteolytic cleavage, their affinity for IGFs is reduced. In the case of IGFBP-3 and -5, the fragments may retain significant affinity for IGFs and, furthermore, may potentiate IGF actions. Preliminary characterization of these proteases has shown that the proteases are calcium-dependent, serine proteases. The exact roles of these proteases in controlling the distribution of IGFs in serum are undetermined. At the same time, the relationship between the activity of the proteases and various pathophysiological conditions should be determined. Serine phosphorylation has been demonstrated for IGFBP-1, -3, and -5 (Jones et al., 1991) . A significant change in affinity for IGF-I after phosphorylation has been proven only for IGFBP-1. Glycosylation has been shown to occur for IGFBP-3, -4, -5 and -6, although only O-linked glycosylation is present in IGFBP-5 and -6. The functional significance of glycosylation has not been determined (Jones and Clemmons, 1995) . In addition, IGFBP-1, -3 and -5 specifically bind to molecules on the cell surface. IGFBP-1 and IGFBP-2 contain an integrin receptor recognition sequence, Arg-Gly-Asp (RGD sequence) which allows them to specifically associate with the α5β1 integrin (fibronectin) receptor . IGFBP-3 and -5 adhere to different molecules that are present on cell surfaces and in ECM. An increase of binding or adherence of IGFBP-1, -3 and -5 on the cell surface may stimulate mitogenesis, by providing a sustained release of IGF-I to the cells. Nevertheless, IGF-independent actions have been also shown for IGFBP-1 and -3 and for a fragment of IGFBP-5. This will be discussed later.
IGFBP-1
IGFBP-1 exists as a non-glycosylated protein of 30 kDa molecular weight , and it is strongly expressed in liver and kidney. Most studies in cell culture systems under serum-free conditions indicate that the addition of purified IGFBP-1 results in inhibited cell growth and/or inhibited differentiated cell function. These inhibitory effects have been attributed to IGFBP-1 interference with IGF ligand-receptor interactions. Definitive inhibition generally occurs when the IGFBP-1 is added in molar excess (usually at least 4:1). Busby et al . (1988) showed that IGFBP-1 purified from amniotic fluid inhibited IGF-I stimulated [ 3 H ] t h y m i d i n e incorporation into porcine aortic smooth muscle cells and fibroblasts. Other cell types that were shown to be inhibited by IGFBP-1 include JEG-3 choriocarcinoma cells, FRTL5 thyroid cells, chick embryo pelvic leaflets, chick embryo fibroblasts, and JMGE-3 osteosarcoma cells (Jones and Clemmons, 1995) . Angervo et al. (1991) showed that IGFBP-1 also inhibited DNA synthesis in cultured human granulosa-luteal cells and postulated that IGFBP-1 may play an important role in lutealization since these cells undergo mitotic arrest during that time, with IGFBP-1 making them refractory to further growth stimulation by IGF-I. IGFBP-1 also inhibits glucose incorporation into BALB/c 3T3-fiboblasts . This is consistent with a possible role of IGFBP-1 in glucose counterregulation; acute administration of IGFBP-1 to rats can reduce the glucose-lowering effect of IGF-I transiently (Lewitt et al., 1991) .
In contrast, IGFBP-1 can potentiate IGF-I action if a low concentration of platelet-poor plasma (PPP) is included in the culture medium. Elgin et al. (1987) have shown that IGFBP-1 potentiates the effect of IGF-I on DNA synthesis in porcine aortic smooth muscle cells in culture medium with a low concentration of PPP. The factor in PPP has been shown to be not dialyzable, heatand acid-stable, and cannot be replaced by the a d d i t i o n of other growth factors (Clemmons and Gardner, 1990) . However, IGFBP-1 can stimulate cell growth in some cell systems (MDA-231 breast carcinoma cell) without added PPP . Koistinen et al. (1990) reported that IGFBP-1 can simul-taneously inhibit binding of IGF-I to cell surfaces and stimulate their mitogenesis, suggesting that IGFBP-1 may be potentiative, by providing a sustained release of IGF-I to receptors. Such potentiation by IGFBP-1 may require its cell association. Busby et al. (1988) reported that there are two isoforms of IGFBP-1 in amniotic fluids that differed in their ability to bind to cell surfaces and to form disulfidelinked multimers. The form that associated with cell surfaces and polymerized, resulted in potentiation of IGF-I action in the presence of PPP, while the other isoform that showed no capability to be associated with cell surfaces and polymerized inhibited IGF action. This finding supports the importance of cell surface association and/or multimer formation of IGFBP-1 for potentiation of IGF action to occur. IGF-mediated actions can be potentiated by the binding of IGFBP-1 to the α5β1 integrin (fibronectin) of which is mediated through an integrin receptor recognition sequence (RGD). In this circumstance, i n t e g r i n -b o u n d IGFBP-1 could act as a reservoir for IGF, which could provide a high concentration of IGF to stimulate the IGF-I receptor. Phosphorylated forms of IGFBP-1 have been observed in human amniotic fluid and fetal serum (Jones et al., 1991) as well as human decidual c u l t u r e s (Frost and Tseng, 1991) , CHO cells transfected with an IGFBP-1 construct and nontransfected Hep G2 cells (Jones et al., 1991) . It has been known that the i s o f o r m s that inhibit IGF action are phosphorylated while the isoform that stimulates IGF action is nonphosphorylated (Busby et al., 1988) . The observations of Westwood et al. (1994) further support this concept. They recently demonstrated that IGFBP-1 in normal plasma exists as a single, highly phosphorylated species (high affinity), while in pregnant maternal plasma and in amniotic fluid, IGFBP-1 is either nonphosphorylated or exhibited reduced phosphorylation (lower affinity), suggesting that the reduced-affinity IGFBP-1 in pregnancy tissues may promote conceptus growth by increasing IGF bioavailability to its receptors.
The roles of IGFBP-1 and its regulation are associated with different physiological or pathophysiological processes. IGFBP-1 expression is strongly and acutely stimulated under catabolic conditions. Both insulindependent diabetes mellitus (IDDM) and the fasting state result in dramatically increased IGFBP-1 mRNA in liver, kidney and other tissues (Lee et al., 1993) . IGFBP-1 expression appears to be regulated by insulin (which is inhibitory) and glucocorticoids (which are stimulatory) associated with catabolic processes. Administration of IGFBP-1 to rats in vivo can induce an elevation of blood glucose (Lewitt et al., 1991) . IGFBP-1 is also involved in a variety of reproductive functions, including endometrial cycling, oocyte maturation, and gestational development (Kelley et al., 1996) . The concentration of IGFBP-1 in amniotic fluid and fetal serum (3000 ng/ml by the second trimester of gestation) is higher than that in maternal serum (about 25 ng/ml) . The elevated levels of high affinity IGFBP-1 in the fetal compartment, combined with reduced and/or proteolyzed (low affinity) IGFBP-3 in the maternal circulation, provide for a gradient down which IGFs can move toward the amniotic fluid and fetal circulation. In diabetic kidney, renal IGFBP-1 mRNA and protein expression are significantly increased and result in an aberrant and activated growth response within the tissue (Landau et al., 1995) , suggesting that IGFBP-1 is a strong candidate both as a local sequesterer of IGFs as well as a possible cellular mediator of the aberrant growth activity.
IGFBP-2
The actions of IGFBP-2 on IGF-mediated functions have been reported to be both inhibitory and stimulatory, although it has received less intensive analysis than IGFBP-1 or -3. IGFBP-2 has been shown to have an RGD sequence and is not glycosylated or phosphorylated.
Purified IGFBP-2 has been shown to inhibit [ 3 H ] t h y m i d i n e incorporation into chick embryo fibroblasts and rat astroglial cells (Knauer and Smith, 1980) , and inhibit the activity of IGF-II to stimulate DNA synthesis in human lung carcinoma cells (Reeve et al., 1993) .
IGFBP-2 has been reported to potentiate IGF action weakly. Addition of IGFBP-2 to microvascular endothelial cells in serum-free medium slightly stimulates cellular glucose transport and aminoisobutyric acid uptake (Bar et al., 1989) . Bourner et al. (1992) have also reported that bovine IGFBP-2 can potentiate IGF-I action in porcine aortic smooth muscle cells in the presence of a low concentration of PPP.
The physiological actions of IGFBP-2 are also not well characterized. IGFBP-2 may be involved in fetal development, particularly in the central nervous system by participating in pituitary development and in the transport of IGF-II to the cerebrospinal fluid . In adults, the IGFBP-2 gene is strongly expressed in the central nervous system and is the major IGFBP in cerebrospinal fluid (Lamson et al., 1989) . The regulation of IGFBP-2 is also associated with metabolism and reproduction. Prolonged fasting and IDDM in rats result in significantly increased IGFBP-2 in liver, although kidney, brain and other tissues show no such changes (Thissen et al., 1994) . IGFBP-2 is also expressed in a number of reproductive tissues and is the most abundant IGFBP in seminal plasma . Cohen et al. (1994a) reported that IGFBP-2 expression in prostatic stromal cells from patients with benign prostatic hyperplasia is significantly reduced and suggested that activated growth in benign prostatic hyperplasia is partly supported by reduced inhibitory IGFBP-2. In lung carcinoma cell lines, IGFBP-2 expression is also reduced, and that works in a same manner.
IGFBP-3
IGFBP-3 has been reported to modulate the action of IGFs both positively and negatively, and may also be capable of IGF-independent inhibitory actions on cell growth. Although IGFBP-3 is expressed as a single protein sequence, there are various forms by posttranslational modifications. These include the various degree of glycosylation during cellular synthesis of IGFBP-3, and proteolytic cleavage in the extracellular environment. Recombinant IGFBP-3 from E.coli (nonglycosylated form) (Sommer et al., 1992) or chemically deglycosylated IGFBP-3 (Martin and Baxter, 1992 ) have a molecular weight of around 29 kDa. By comparison, IGFBP-3 is heavily glycosylated on two (human) or three (rat) Nlinked and two potential O-linked glycosylation sites and is usually produced as a doublet of 43 and 45 kDa (Baxter, 1994) . There are no significant differences in affinity for IGF-I between nonglycosylated and glycosylated IGFBP-3. Serine phosphorylation of IGFBP-3 has also been reported, although site-directed mutagenesis of two of the phosphorylated serines did not affect IGF binding activity (Hoeck and Mukku, 1994) .
IGFBP-3 is a well-documented inhibitor of cellular proliferation and differentiation. Excess of purified IGFBP-3, when added together with IGF-I to human skin fibroblast, could inhibit IGF-I stimulated DNA synthesis (DeMellow and Baxter, 1988) . IGFBP-3 has also been shown to inhibit glucose incorporation in BALB/c 3T3 cells , IGF-I stimulated cAMP generation and DNA synthesis in rat granulosa cells (Bicsak et al., 1990) , and IGF-I stimulated DNA and collagen synthesis in rat osteoblasts (Schmid et al., 1991) . Preincubation with IGFBP-3 alone also resulted in inhibition of subsequent effects of IGF-I or IGF-II. The mechanism by which IGFBP-3 inhibits IGF action is related to its ability to inhibit IGF binding to IGF-I receptors.
In contrast, Cornell et al. (1986) have demonstrated that IGFBP-3 could potentiate the effects of IGF on glucose incorporation, which is not consistent with other observations (DeMellow and Baxter, 1988) . These conflicting results can be attributed to the difference in treatment with IGFBP-3. Preincubation of human fibroblasts with IGFBP-3 followed by its removal resulted in substantial potentiation of the effect of IGF-I on DNA synthesis, whereas coincubation resulted in inhibition. Conover et al. (1990) showed that bovine IGFBP-3 affected the aminoisobutyric acid uptake response to IGF-I in fibroblast cultures in the same manner. Potentiation of IGF action by IGFBP-3 appears to require its cellsurface association. Since IGFBP-3 in solution has a higher affinity for IGFs than does the type-1 IGF receptor, IGFBP-3 in solution works as a strong competitive inhibitor of IGFs. However, cell association of IGFBP-3 results in a 10-fold-reduced affinity for IGF-I compared with IGFBP-3 in solution (McCusker et al., 1990; Conover, 1991) , and therefore it is capable of modulating IGF receptor interactions such that IGFs are more available for receptor binding. Conover (1991) reported that glycosylation of IGFBP-3 was not required for binding to cell surfaces or potentiating IGF-I action. Conover (1991) furthermore suggested that the IGFBP-3 that adhered to the cell surface was processed to a lower molecular weight forms, and that these had a lower affinity for IGF-I. Proteolysis of IGFBP-3 may thus be important for the potentiative action of IGFBP-3. Schmid et al. (1991) have reported that truncated IGFBP-3 (28-30 kDa IGFBP-3 fragment) potentiated IGF-I action, whereas intact IGFBP-3 inhibited IGF-I action on thymidine incorporation into DNA in a rat osteoblast cell line. In prostate epithelial cells, proteolysis of IGFBP-3 resulted in a loss of inhibition by IGFBP-3 on IGF-I-mediated cell growth (Cohen et al., 1994b) . These data indicate that cell association and/or local proteolysis of IGFBP-3 may modulate its cellular activity and cells can regulate the bioavailability of IGFs through the use of proteases.
Serum proteolysis of IGFBP-3 is likely to exist to some degree under different physiological or pathophysiological conditions to regulate the availability of IGFs. The proteolysis of IGFBP-3 has been known firstly from the studies on serum IGFBP levels during pregnancy (Fielder et al., 1990; Giudice et al., 1990; Hossenlopp et al., 1990) . The predominant IGFBP-3 in pregnancy serum is a proteolyzed fragment of 28-30 kDa (Fielder et al., 1990) . This fragment binds IGF-I with reduced affinity, but can still exist in the ternary complex with acid-labile subunit and IGF (Bang et al., 1994a) . The source of the pregnancy IGFBP-3 protease appears to be the decidua (Davenport et al., 1992) . Bang et al. (1994b) recently reported that in serum from patients with NIDDM, an IGFBP-3 protease produces a 28-30 kDa IGFBP-3 fragment similar to that produced by the pregnancy IGFBP-3 protease. Recently, other proteases were found in prostate cancer (identified as prostate specific antigen) (Cohen et al., 1994b) , and in cultured prostatic cells (identified as cathepsin D) .
More recently, Buckbinder et al. (1995) demonstrated that induction of IGFBP-3 gene expression by wild-type, but not mutant, p53 is associated with enhanced secretion of an active form of IGFBP-3 capable of inhibiting mitogenic signalling by IGF-I. Their results indicate that IGFBP-3 may link p53 to potential novel autocrine/ paracrine signalling pathways and to processes regulated by or dependent on IGFs, such as cellular growth, transformation and survival.
IGFBP-4
IGFBP-4 appears to inhibit IGF actions under most experimental conditions, and to date there have been no reports to indicate a potentiative action of IGFBP-4 at the cellular level. IGFBP-4 contains one N-l i n k e d glycosylation site, and exists in biological fluids as a doublet: a 24-kDa nonglycosylated form and a 28-kDa glycosylated form. The physiological significance of glycosylated IGFBP-4 has not been determined. IGFBP-4 does not seem to adhere to cell surfaces. Proteolysis of IGFBP-4 results in proteolytic fragments (14 and 18 kDa) that have very low or no IGF binding capacity.
IGFBP-4 was initially isolated on the basis of its inhibition of IGF-stimulated cell proliferation. Mohan et al . (1989) isolated this binding protein from an osteosarcoma cell line, and showed that it was a potent inhibitor of IGF action. Ui et al. (1989) isolated IGFBP-4 on the basis of its ability to inhibit steroidogenesis in rat granulosa cells. Likewise, Culouscou et al. (1991) purified IGFBP-4 on the basis of its ability to inhibit the growth of a colon carcinoma cell line. The mechanism by which IGFBP-4 inhibits IGF-mediated cell functions is by the binding of IGFBP-4 to IGFs, thereby preventing the interaction of the IGFs with their receptors (Kiefer et al., 1992) . This inhibitory effect of IGFBP-4 can be relieved by proteolysis, and this provides for a cellular mechanism to increase local IGF concentrations. IGFBP-4 proteases were found in a variety of cell types, including fibroblasts , smooth muscle cells (Cohik et al., 1993) , neuroblastoma (Cheung et al., 1994) , bone-derived cells (Durham et al., 1994) , and prostate (Lee et al., 1994) . Since IGFBP-4 proteases are specific, they do not proteolyze the other IGFBPs, and these proteases are activated in the presence of IGF-I or IGF-II (Neely and Rosenfeld, 1992) . Activation of proteolysis by IGF can occur under cell-free conditions and appears to be the result of IGF binding to IGFBP-4. reported that IGF-II may be more effective that IGF-I in activating IGFBP-4 proteolysis, and suggested a mechanism wherein low concentrations of IGF-II could increase local availability of IGF-I. Glucocorticoids (Okazaki et al. , 1994) , para-thyroid hormone (LaTour et al., 1990) , growth hormone , and 1,25-dihydroxyvitamin D3 (Scharla et al., 1991) have also been known to influence IGFBP-4 and/or its susceptibility to proteolysis in bone cells.
The physiological regulation of IGFBP-4 and its protease is poorly understood. Rodgers et al. (1995) reported that circulating IGFBP-4 levels are significantly reduced in uncontrolled IDDM. He also proposed that in vivo IGFBP-4 could be considered growth promoting, by showing that tibial epiphyseal plate width was positively correlated with IGFBP-4 concentrations in diabetic rats.
IGFBP-5
IGFBP-5 has a molecular weight of 29 kDa, has no Nlinked glycosylation sites, but exhibits O-linked glycosylation . Serine phosphorylation of IGFBP-5 has also been reported (Jones et al., 1991) .
IGFBP-5 has been shown to inhibit IGF-I-stimulated DNA and glycogen synthesis in human osteosarcoma cells when a molar excess of IGFBP-5 was used (Kiefer et al., 1992) . Ling et al. (1993) has also reported that inhibition of steroidogenesis in granulosa cells stimulated with IGF-I, suggesting that IGFBP-5 had an inhibitory function.
IGFBP-5 has been shown to adhere to fibroblast ECM. When IGFBP-5 was incubated with ECM, it potentiated the effect of IGF-I on cell growth by approximately 100% (Jones et al., 1993b) . IGFBP-5 added to the medium was cleaved to a 21-kDa fragment, while IGFBP-5, either added exogeneously to the ECM or synthesized by fibroblasts and bound to ECM was present only in an intact form, suggesting that proteolysis of IGFBP-5 could be prevented by binding to ECM. Proteolyzed IGFBP-5 fragments did not potentiate the action of IGF-I. Since the ECM-associated IGFBP-5 has lower affinity for IGF-I by approximately 7-fold, ECM-associated IGF-I could act as a reservior for release of IGF for cell surface receptors. The binding of IGFBP-5 to ECM results in the potentiation of IGF-mediated cell functions by lowering of IGFBP-5 affinity for IGF and protecting it from proteolysis. Cell surface association of IGFBP-5 may also mediate its ability to potentiate IGF actions. Jones et al. (1993b) suggested this as a mechanism whereby cell-associated IGFBP-5 serves as a stable IGF-binding site and, with its reduced affinity, promotes IGF ligand-receptor interaction. As described earlier, when IGFBP-4 binds to IGF, its proteolysis is stimulated, which results in reduced affinity for IGF. However, IGFBP-5 is protected from proteolysis when bound to IGF . Proteolysis of recombinant IGFBP-5 (29 kDa) results in proteolytic fragments of 20, 17 and 16 kDa, and similar IGFBP-5-immunoreactive fragments have been observed in human serum (Kiefer et al., 1992) . Andress and Bimbaum (1992) reported that a 23-kDa IGFBP-5 fragment (truncated at the C-terminus) purified from U-2 cells had a highly reduced affinity for IGFs and potentiated IGF-I-stimulated mitogenesis in both U-2 cells and in normal mouse osteoblasts. A serine protease that cleaves IGFBP-5 was found in human fibroblast conditioned medium by Nam et al. (1994) . Active fractions obtained from a heparin-Sepharose column exhibited proteolytic activity specific for IGFBP-5 and resulted in IGFBP-5 fragments of 22, 20 and 17 kDa. It was found that heparin inhibited IGFBP-5 proteolysis, suggesting that the basic region within IGFBP-5 that is important for its ECM association may also be the site at which IGFBP-5 proteases cleave (Bar et al., 1994) . Similar fragments resulting from proteolysis of IGFBP-5 have been reported in follicle stimulating hormone (FSH)-stimulated rat granulosa cells (Fielder et al., 1993) and in seminal plasma (Lee et al., 1994) . Bautista et al. (1991) have also demonstrated that addition of equimolar concentrations of IGF-II and IGFBP-5 in mouse MC3T3-E1 osteoblast culture resulted in potentiation of IGF-II action.
IGFBP-5 is the predominant IGFBP in bone extracts, and is believed to function in the bone matrix to fix IGFs in the tissue and to promote IGF ligand-receptor interaction. In addition, IGFBP-5 appears to play a significant role in ovarian function. IGFBP-5 and IGFBP-4 are predominantly expressed in the granulosa cells in rat. In healthy follicles, IGFBP-5 and IGFBP-4 expression is inhibited, while the opposite is true in degenerative, atretic follicles, suggesting that the intrafollicular levels of IGFBP-5 and IGFBP-4 may be important determinants of follicular selection (Adashi, 1994) . IGFBP-5 is also associated with growth inhibition in the kidney. In the kidney, IGFBP-5 is the most abundantly expressed IGFBP, and its expression in vivo appears to be inversely related to renal growth activity . Landau et al . (1995) observed that renal expression of IGFBP-5, as well as of IGFBP-3, was significantly reduced early in the onset of IDDM, suggesting that, in addition to increased IGFBP-1, which might sequester IGFs locally, diabetic renal disease might also be characterized by a relief from inhibition by IGFBP-5 and IGFBP-3.
IGFBP-6
Since IGFBP-6 is rather recently isolated and cloned, studies are limited. IGFBP-6 exists as a 30-kDa protein and seems to have only O-linked glycosylation, although it contains one N-linked glycosylation site (Bach et al., 1993) . Deglycosylated or recombinant (nonglycosylated) IGFBP-6 is approximately 24-25 kDa (Kiefer et al., 1992) . Although IGFBP-6 contains a heparin-binding consensus domain, recombinant IGFBP-6 does not specifically bind endothelial cell monolayers and has a low affinity for heparin (Bar et al., 1994) . No IGFBP-6 protease has yet been identified. IGFBP-6 has been shown to have a markedly lower affinity for IGF-I than for IGF-II (Kiefer et a l., 1992) . IGFBP-6 is detected in cerebrospinal fluid, serum, and in other fluids (Baxter and Saunders, 1992) . Serum levels of IGFBP-6, although low, are found to be lower in females and are further reduced during pregnancy.
IGFBP-6 appears to have an antigonadotropic activity in the rat ovary (Rohan et al., 1993) . FSH treatment significantly reduces tissue IGFBP-6 expression in rats, suggesting that IGFBP-6 may antagonize follicular development. However, recombinant human IGFBP-6 had no inhibitory effect on FSH-stimulated steroidogenesis in rat granulosa cells in culture. Zhou et al. (1994) have recently reported that IGFBP-6 expression is increased during the secretory phase of the menstrual cycle, suggesting that IGFBP-6 may be associated with endometrial cycling.
IGF-independent actions of the IGFBPs

IGFBP-1
IGFBP-1 (and IGFBP-2) contains an integrin receptor recognition sequence, Arg-Gly-Asp (RGD sequence) which allows it to specifically bind the a5b1 integrin (fibronectin) receptor . Jones et al. (1993a) have demonstrated that IGFBP-1 binds specifically to the a5b1 integrin receptor and showed the functional significance of this interaction in cultured Chinese hamster ovary (CHO) cells. The expression of recombinant IGFBP-1 by CHO cells or the addition of IGFBP-1 to the culture medium stimulated cell migration. In contrast, mutation of the RGD sequence to Trp-GlyAsp (WGD) in IGFBP-1 by in vitro mutagenesis prevented it from binding to the integrin receptor or stimulating cell migration. The addition of a synthetic RGD-containing peptide to the culture medium with IGFBP-1 resulted in blockage of the effect of IGFBP-1 on cell migration. The effect on migration of IGFBP-1 in this system was independent of IGF-I, since 1) the WGD mutation did not affect binding affinity for IGF-I, 2) addition of IGF-I to the medium had no effect on cell migration, and 3) no endogenous IGF-I or IGF-II or their mRNAs could be detected.
IGFBP-3
Several recent lines of evidence have indicated that IGFBP-3 by itself has intrinsic inhibitory effects on cells, independent of its interaction with IGF. Villaudy et al. (1991) showed that IGFBP-3 inhibited DNA synthesis in mouse embryo fibroblasts that had been stimulated by basic fibroblast growth factor (FGF), even in the presence of 1000 ng/ml insulin. Since the IGF-I receptors were occupied by insulin at high concentrations, this finding suggested that IGF receptor occupancy was not related to IGFBP-3 action. Imbenotte et al. (1992) demonstrated that IGFBP-3 also inhibited chick embryo fibroblast replication stimulated by transforming growth factor β ( T G F -β). Similarly, IGFBP-3 was found to be more effective than IGF-I-immunoneutralization in inhibiting serum-stimulated DNA synthesis . Cohen et al. (1993) reported that, in BALB/c3T3 fibroblasts, overexpression of a transfected human IGFBP-3 cDNA strongly inhibits cell proliferation, with or without added IGF. Oh et al. (1993a) have demonstrated that IGFBP-3 binds on the cell surface and can inhibit Hs578T human breast cancer cell monolayer growth by itself. They showed that the inhibitory effect of IGFBP-3 was specific and IGF-independent by demonstrating: 1) dose-dependent inhibition on cell growth and on DNA synthesis by IGFBP-3, but not by IGFBP-1; 2) absence of stimulatory effects on monolayer Hs578T cell growth by either IGFs or IGF analogs; and 3) significant diminution of the IGFBP-3 inhibitory effects by coincubation with IGFs, but not with IGF analogs with decreased affinity for IGFBPs. Subsequently, Oh et al.(1993b) have demonstrated cell surface association proteins of 50, 26 and 20 kDa that are specific for IGFBP-3, by affinity cross-linking and immunoprecipitation. IGFBP-3-mediated inhibition of cell growth was cation-dependent and blocked by IGF-I and IGF-II, but not by IGF analogs with decreased affinity for IGFBPs, suggesting that these cell surface proteins mediate the direct inhibitory effects of IGFBP-3. The biochemical nature of these proteins has not been determined.
The role of IGFBP-3 as a mediator of cell growth inhibition may be a common feature in the control of cell regulation by other growth factors (Kelley et al., 1996) . T G F -β is a potent growth inhibitor in human breast cancer cells in vitro and appears to regulate IGFBP-3 production. Oh et al. (1995) have recently demonstrated, using Hs578T cells that TGF-β stimulates IGFBP-3 gene expression, and treatment with an IGFBP-3 antisense oligodeoxynucleotide selectively inhibits TGF-β-induced IGFBP-3 synthesis and cell growth inhibition. Gucev et a l. (1995) further showed that retinoic acid, also a potent growth inhibitor in breast cancer cells, inhibits cell growth through a similar modulation of IGFBP-3 expression. These data suggest that IGFBP-3, through intrinsic activity, is an important cellular growth regulator and may also be an important mediator for other cellular growth factors (Kelley et al., 1996) .
IGFBP-5
The functional significance of IGFBP-5 proteolysis may be found in studies by Andress and Birnbaum (1992) using a 23-kDa IGFBP-5 fragment purified from U-2 cells. They reported that a 23-kDa IGFBP-5 fragment stimulated mitogenesis in an apparent IGF-independent manner, since simultaneous addition of excess IGFBP-3 sufficient to sequester local IGFs did not interfere with the stimulation. Furthermore, they showed that the osteoblast-derived IGFBP-5 stimulated mitogenesis in the absence of exogenous or endogenous IGF, and the binding protein could associate with the osteoblast surface, an effect which did not require IGF or an interaction with the IGF receptors.
New concepts of IGFBPs
IGFBP-7
Much less is known about newly identified family of IGFBP. The IGFBP-7 cDNA clones have been isolated from human leptomeningioma cells (Murphy et al., 1993) and mammary epithelial cells (Swisshelm et al ., 1995) . IGFBP-7 exists as a major 27-kDa protein and a minor higher molecular weight protein of 54 kDa (presumably dimers of the IGFBP-7 protein) and appears to have one N-linked glycosylation site; deglycosylated IGFBP-7 is around 25 kDa . Uniquely among the IGFBPs, IGFBP-7 has a markedly reduced affinity for IGFs; Compared with IGFBP-3, the affinity of IGFBP-7 for IGFs appears to be approximately 5-25-fold lower . Although the concentration of IGFBP-7 in serum is very low, IGFBP-7 can be detected in various body fluids including in normal human urine, cerebrospinal fluid and amniotic fluid .
Physiological significance of IGFBP-7 has not been determined. Swisshelm et al . (1995) have reported that expression of mac25/IGFBP-7 mRNA was elevated in senescent human mammary epithelial cells, while apparently downregulated in mammary carcinoma cell lines. Furthermore, mac25/IGFBP-7 mRNA is up-regulated in normal, growing mammary epithelial cells by allt r a n s-retinoic acid (RA), suggesting that IGFBP-7 may be a downstream effector of the RA-induced senescence pathway. Taken together with the result showing reduced IGFBP-7 mRNA levels in several cancers such as breast, prostate, colon and lung , IGFBP-7 may function not only as an IGF binding protein, but also as a direct growth-suppressing factor, with an IGF-independent action similar to that of IGFBP-3. Recently, Oh et al. (1997) have demonstrated that IGFBP-7 is a growth-suppressing factor in breast cancer and it's IGF-independent action and role in mediating TGF-β-induced growth inhibition may involve interaction with DNA, RNA or nuclear proteins.
Potential candidates of new IGFBPs
A closely related family of genes encoding CTGF (Bradham et al., 1991) , the nov oncogene (Martinerie et al., 1992) , and cyr61 (O'Brien et al., 1990) has been identified; the predicted proteins are products of "immediate-early genes" expressed after induction by serum, growth factors or certain oncogenes. Sequence comparison between any member of this new family and IGFBPs shows similarities between 30-38%. Moreover, these proteins also contain the conserved "GFBP motif" (GCGCCXXC) in their aminoterminus and as many as 17 of the 18 cysteines conserved in IGFBPs-1-6 (Figure 1) , suggesting that the CTGF/n o vo n c o g e n e /c y r61 family shares significant structural homology with IGFBPs (Bork, 1993) and may potentially bind IGFs. Kim et al. (1997) have demonstrated that CTGF specifically binds IGFs, with relatively low affinity, suggesting that CTGF meets criteria that define it as a new member of the IGFBP family, IGFBP-8. They have further proposed that the six high-affinity IGFBPs and the four potential low-affinity IGFBPs constitute a superfamily of proteins that regulate cell growth through both IGFdependent and IGF-independent actions (Figure 2 ).
